BioLineRx Beheer

Beheer criteriumcontroles 2/4

De CEO BioLineRx is Phil Serlin, benoemd in Oct2016, heeft een ambtstermijn van 8.08 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 952.00K, bestaande uit 29.4% salaris en 70.6% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 0.014% van de aandelen van het bedrijf, ter waarde € 3.65K. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 7.8 jaar en 2.9 jaar.

Belangrijke informatie

Phil Serlin

Algemeen directeur

US$952.0k

Totale compensatie

Percentage CEO-salaris	29.4%
Dienstverband CEO	8.1yrs
Eigendom CEO	0.01%
Management gemiddelde ambtstermijn	7.8yrs
Gemiddelde ambtstermijn bestuur	2.9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Phil Serlin's beloning veranderd ten opzichte van BioLineRx's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2024	n/a	n/a	-US$20m
Jun 30 2024	n/a	n/a	-US$30m
Mar 31 2024	n/a	n/a	-US$49m
Dec 31 2023	US$952k	US$280k	-US$61m
Sep 30 2023	n/a	n/a	-US$52m
Jun 30 2023	n/a	n/a	-US$43m
Mar 31 2023	n/a	n/a	-US$32m
Dec 31 2022	US$1m	US$297k	-US$25m
Sep 30 2022	n/a	n/a	-US$24m
Jun 30 2022	n/a	n/a	-US$22m
Mar 31 2022	n/a	n/a	-US$22m
Dec 31 2021	US$903k	US$290k	-US$27m
Sep 30 2021	n/a	n/a	-US$35m
Jun 30 2021	n/a	n/a	-US$34m
Mar 31 2021	n/a	n/a	-US$34m
Dec 31 2020	US$958k	US$250k	-US$30m
Sep 30 2020	n/a	n/a	-US$28m
Jun 30 2020	n/a	n/a	-US$27m
Mar 31 2020	n/a	n/a	-US$26m
Dec 31 2019	US$678k	US$256k	-US$25m
Sep 30 2019	n/a	n/a	-US$21m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$23m
Dec 31 2018	US$846k	US$254k	-US$23m
Sep 30 2018	n/a	n/a	-US$25m
Jun 30 2018	n/a	n/a	-US$26m
Mar 31 2018	n/a	n/a	-US$26m
Dec 31 2017	US$612k	US$240k	-US$24m

Compensatie versus markt: De totale vergoeding ($USD 952.00K ) Phil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Phil is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

Phil Serlin (64 yo)

8.1yrs

Tenure

US$952,000

Compensatie

Mr. Philip A. Serlin, also known as Phil, CPA, MBA has been the Chief Executive Officer at BioLineRx, Ltd., since October 10, 2016. Mr. Serlin served as the Chief Financial and Operating Officer of BioLine...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Philip Serlin	Chief Executive Officer	8.1yrs	US$952.00k	0.014% € 3.6k
Mali Zeevi	Chief Financial Officer	8.1yrs	US$443.00k	0.027% € 7.0k
Ella Sorani	Chief Development Officer	7.8yrs	US$520.00k	0.0055% € 1.4k
Holly May	President of BioLineRx USA	2.4yrs	US$1.01m	geen gegevens
John Lacey	Head of Corporate Communications & Investor Relations	no data	geen gegevens	geen gegevens
Tsipi Keren-Lehrer	Head of BD & Strategic Advisor	5.3yrs	geen gegevens	geen gegevens
Raziel Fried	Treasurer & Budgetary Control Director	no data	geen gegevens	geen gegevens

7.8yrs

Gemiddelde duur

59yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van YP2A is doorgewinterd en ervaren (gemiddelde ambtstermijn van 7.8 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Aharon Schwartz	Chairman of the Board	20.8yrs	geen gegevens	0.31% € 78.6k
Sandra Panem	Director	10.8yrs	geen gegevens	geen gegevens
Avraham Molcho	Independent External Director	14.3yrs	US$26.55k	geen gegevens
Raphael Hofstein	Director	21.8yrs	US$140.92k	geen gegevens
Ronald Levy	Member of Immuno-Oncology Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Rami Dar	Independent External Director	2.3yrs	geen gegevens	geen gegevens
Gal Cohen	Independent Director	less than a year	geen gegevens	geen gegevens
Barbar-Jean Bormann-Kennedy	Director	11.3yrs	geen gegevens	geen gegevens
Jon Marc Wigginton	Member of Immuno-Oncology Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Ignacio Melero Bermejo	Member of Immuno-Oncology Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Aurelien Marabelle	Member of Immuno-Oncology Scientific Advisory Board	2.9yrs	geen gegevens	geen gegevens
Shaoyu Yan	Director	less than a year	geen gegevens	geen gegevens

2.9yrs

Gemiddelde duur

66yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van YP2A wordt niet als ervaren beschouwd (gemiddelde ambtstermijn 2.9 jaar), wat duidt op een nieuw bestuur.

BioLineRx Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

Recent updates

BioLineRx Ltd. has filed a Follow-on Equity Offering in the amount of $8.998765 million.

BioLineRx Ltd. to Report Q3, 2024 Results on Nov 25, 2024

Biolinerx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for Cd34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease At Ash 2024

BioLineRx Ltd. Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide

BioLineRx Ltd., Annual General Meeting, Oct 01, 2024

BioLineRx Ltd. to Report Q2, 2024 Results on Aug 15, 2024

BioLineRx Ltd Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization For Gene Therapy Applications in Sickle Cell Disease

BioLineRx Ltd. Announces Abstract on Pilot Study Data from Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer at American Society of Clinical Oncology

BioLineRx Ltd. to Report Q1, 2024 Results on May 28, 2024

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

BioLineRx Ltd. Announces Poster Presentation on Apheresis Center Efficiency and CXCR4 Antagonists Including APHEXDA® (Motixafortide) in Patients with Multiple Myeloma at the ASFA 2024 Annual Meeting

BioLineRx Ltd. to Report Fiscal Year 2023 Results on Mar 26, 2024

BioLineRx Strengthens Intellectual Property Estate with Notice of Allowance for U.S. Patent Covering Method of Manufacturing Motixafortide (Bl-8040) Suitable for Large Scale Production

Biolinerx Announces First Patient Dosed in Randomized Phase 2 Combination Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer

BioLineRx Ltd. Announces Acceptance of Two Poster Presentations on APHEXDA®? (Motixafortide) for CD34+ Hematopoietic Stem Cell (HSC) Mobilization in Patients with Multiple Myeloma at the 2024 Tandem Meetings of ASTCT®?

BioLineRx Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease

BioLineRx Ltd. Appoints Gal Cohen to Its Board as a Class I Director

BioLineRx Ltd. to Report Q3, 2023 Results on Nov 20, 2023

BioLineRx Ltd. announced that it has received $14.6 million in funding

Biolinerx Ltd. Announces Encouraging Data from Pilot Phase of Phase 2 Combination Clinical Trial with Motixafortide in First-Line Pancreatic Cancer (Pdac)

BioLineRx Ltd Announces FDA Approval of APHEXDA™ (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma

BioLineRx Ltd. to Report Q2, 2023 Results on Aug 30, 2023

BioLineRx Ltd. Announces Initiation of Randomized Phase 2 Clinical Trial in First Line Metastatic Pancreatic Cancer Based on Preliminary Data from Single-Arm Pilot Phase

BioLineRx Ltd., Annual General Meeting, Aug 07, 2023

BioLineRx Ltd. to Report Q1, 2023 Results on May 24, 2023

Rosen Law Firm Encourages Biolinerx Ltd. Investors with Losses to Secure Counsel Before Important Deadline

Rosen Law Firm Files Securities Class Action Lawsuit on Behalf of BioLineRx Ltd

BioLineRx Ltd. Appoints Tami Rachmilewitz, M.D., as Chief Medical Officer

BioLineRx Ltd. Announces Results from Phase 1/2a Study of Investigational Anti-Tumor Vaccine AGI-134 in Metastatic Solid Tumors

BioLineRx Ltd. Announces U.S. FDA Acceptance of New Drug Application for Aphexda® (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Receipt of Nasdaq Minimum Bid Price Notification

Biolinerx Ltd. Announces U.S. Commercialization Plan for Aphexda (Motixafortide) in Stem Cell Mobilization

BioLineRx Announces Submission of New Drug Application to U.S. Food and Drug Administration for Motixafortide in Stem Cell Mobilization

BioLineRx Ltd. to Report Q2, 2022 Results on Aug 16, 2022

BioLineRx Ltd. Appoints Holly W. May as its Chief Commercial Officer

BioLineRx Ltd., Annual General Meeting, Jul 03, 2022

BioLineRx Ltd. to Report Q1, 2022 Results on May 11, 2022

BioLineRx Ltd. Announces Additional Positive Results from Pharmacoeconomic Study Comparing Motixafortide + G-CSF to Plerixafor + G-CSF in Stem Cell Mobilization

BioLineRx Announces Completion of Enrollment of Phase 1/2A Study of Innovative Intratumoral Cancer Vaccine, AGI-134, in Unresectable Metastatic Solid Tumors

BioLineRx Ltd. Announces Successful Completion of Pre-NDA Meeting with FDA for Motixafortide for Stem Cell Mobilization in Multiple Myeloma Patients

BioLineRx Ltd. Announces Positive Top-Line Results from GENESIS Phase 3 Trial of Motixafortide in Stem-Cell Mobilization for Autologous Bone Marrow Transplantation in Multiple Myeloma Patients

BioLineRx Ltd. to Report Fiscal Year 2020 Results on Feb 23, 2021

BioLineRx Ltd. Announces Final Results from Phase 2a COMBAT/KEYNOTE-202 Triple Combination Study of Motixafortide in Second Line Metastatic Pancreatic Cancer (PDAC)

BioLineRx Ltd. to Report Q3, 2020 Results on Nov 23, 2020

BioLineRx Ltd. Announces Initiation of Phase 1B Clinical Trial in Patients with Acute Respiratory Distress Syndrome Secondary to Covid-19 and Other Respiratory Viral Infections

BioLineRx Announces Positive Results from Interim Analysis of GENESIS Phase 3 Trial of Motixafortide (BL-8040) in Stem Cell Mobilization

BioLineRx Ltd. has completed a Follow-on Equity Offering.

BioLineRx Ltd. to Report Q2, 2020 Results on Aug 06, 2020

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd